See more : Divi’s Laboratories Limited (DIVISLAB.NS) Income Statement Analysis – Financial Results
Complete financial analysis of HeartBeam, Inc. (BEAT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of HeartBeam, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- Cloudera, Inc. (0I0N.L) Income Statement Analysis – Financial Results
- SNGN Romgaz SA (SNGR.L) Income Statement Analysis – Financial Results
- GUJARAT INJECT (KERALA) LTD. (GUJINJEC.BO) Income Statement Analysis – Financial Results
- Hindware Home Innovation Limited (HINDWAREAP.NS) Income Statement Analysis – Financial Results
- Carbon Race Corp. (CBRJ) Income Statement Analysis – Financial Results
HeartBeam, Inc. (BEAT)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.heartbeam.com
About HeartBeam, Inc.
HeartBeam, Inc., a medical technology company, primarily focuses on telemedicine solutions for the detection and monitoring of cardiac disease outside a healthcare facility setting. The company also focuses on providing diagnostic data to physicians with care management of patients with cardiovascular disease. Its telehealth product comprises a credit card sized electrocardiogram machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is headquartered in Santa Clara, California.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 399.47M | 286.78M | 208.33M | 178.51M | 166.58M | 129.50M | 111.49M | 119.02M | 119.92M | 140.62M | 120.45M | 72.99M | 33.92M | 30.94M | 22.23M | 7.92M |
Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 148.99M | 114.41M | 78.88M | 71.96M | 73.11M | 50.43M | 45.59M | 49.08M | 47.49M | 48.69M | 39.91M | 25.53M | 12.70M | 0.00 | 16.97M | 5.66M |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 250.49M | 172.37M | 129.45M | 106.56M | 93.46M | 79.07M | 65.90M | 69.95M | 72.43M | 91.93M | 80.54M | 47.47M | 21.22M | 30.94M | 5.26M | 2.26M |
Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 62.70% | 60.11% | 62.14% | 59.69% | 56.11% | 61.06% | 59.11% | 58.77% | 60.40% | 65.38% | 66.86% | 65.03% | 62.56% | 100.00% | 23.66% | 28.51% |
Research & Development | 6.80M | 5.68M | 255.00K | 133.00K | 41.00K | 11.21M | 11.10M | 8.36M | 7.11M | 7.40M | 7.34M | 4.66M | 5.70M | 4.90M | 5.81M | 4.00M | 3.78M | 3.63M | 0.00 | 2.41M | 4.44M |
General & Administrative | 8.52M | 7.35M | 2.03M | 655.00K | 0.00 | 112.43M | 88.60M | 56.60M | 47.93M | 45.80M | 37.06M | 33.42M | 35.01M | 34.66M | 39.15M | 41.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 42.85M | 35.32M | 28.64M | 27.94M | 28.81M | 26.28M | 25.60M | 27.82M | 29.34M | 34.66M | 21.11M | 0.00 | 0.00 | 0.00 | 7.70M | 3.53M |
SG&A | 8.52M | 7.35M | 2.03M | 655.00K | 253.00K | 155.28M | 123.92M | 85.23M | 75.87M | 74.61M | 63.34M | 59.03M | 62.83M | 64.00M | 73.81M | 63.03M | 0.00 | 0.00 | 0.00 | 7.70M | 3.53M |
Other Expenses | 0.00 | 3.00K | 22.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.08M | 18.58M | 19.98M | -1.06M | 43.44M | 22.08M | 0.00 | 15.25M | 7.02M |
Operating Expenses | 15.31M | 13.03M | 2.29M | 788.00K | 294.00K | 166.48M | 135.02M | 93.59M | 82.98M | 82.00M | 70.67M | 63.69M | 80.61M | 87.47M | 99.60M | 65.97M | 47.22M | 25.71M | 0.00 | 25.36M | 14.99M |
Cost & Expenses | 15.31M | 13.03M | 2.29M | 788.00K | 294.00K | 315.47M | 249.43M | 172.47M | 154.94M | 155.12M | 121.11M | 109.28M | 129.69M | 134.96M | 148.29M | 105.88M | 72.75M | 38.41M | 0.00 | 42.33M | 20.65M |
Interest Income | 675.00K | 66.00K | 2.17K | 280.00 | 242.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 0.00 | 66.00K | 2.17M | 280.00K | 242.00K | 9.43M | 4.90M | 0.00 | 0.00 | 0.00 | 0.00 | 299.00K | 0.00 | 3.00K | 12.00K | 170.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 15.31M | 13.03M | 2.29M | 788.00K | 294.00K | 40.17M | 28.56M | 14.27M | 12.49M | 12.55M | 12.32M | 9.38M | 12.13M | 12.07M | 10.94M | 8.69M | 4.55M | 2.66M | -42.40M | -848.00K | 46.00K |
EBITDA | 675.00K | -13.03M | 0.00 | -788.00K | -294.00K | 92.05M | 24.25M | 30.04M | 20.38M | 444.00K | 5.21M | -3.43M | -49.05M | -7.52M | -9.52M | 19.55M | 4.19M | -4.99M | -11.46M | -20.95M | -12.68M |
EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 23.04% | 8.46% | 14.42% | 11.42% | 0.27% | 4.03% | -3.08% | -41.21% | -6.27% | -6.77% | 16.23% | 5.74% | -14.71% | -37.05% | -94.22% | -160.04% |
Operating Income | -15.31M | -13.03M | -2.29M | -788.00K | -294.00K | 84.00M | 37.35M | 35.86M | 23.58M | 11.46M | 8.40M | 2.21M | -10.66M | -15.04M | -7.67M | 14.57M | 241.61K | -4.49M | 30.94M | -20.10M | -12.73M |
Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 21.03% | 13.02% | 17.21% | 13.21% | 6.88% | 6.48% | 1.98% | -8.96% | -12.54% | -5.45% | 12.10% | 0.33% | -13.23% | 100.00% | -90.41% | -160.62% |
Total Other Income/Expenses | 675.00K | 69.00K | -2.14M | -280.00K | -242.00K | -42.50M | -47.75M | -20.09M | -15.68M | -23.57M | -15.50M | -15.32M | -50.51M | -4.56M | -12.80M | -3.88M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income Before Tax | -14.64M | -12.96M | -4.43M | -1.07M | -536.00K | 41.50M | -10.40M | 15.77M | 7.90M | -12.11M | -7.10M | -13.11M | -61.18M | -19.60M | -20.47M | 10.69M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 10.39% | -3.63% | 7.57% | 4.42% | -7.27% | -5.49% | -11.76% | -51.40% | -16.34% | -14.56% | 8.87% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 0.00 | -135.00K | 2.17M | 280.00K | 242.00K | -370.00K | 6.75M | -37.67M | 468.00K | -2.31M | 215.00K | -905.00K | 244.00K | 262.00K | 5.00K | 1.48M | 0.00 | 0.00 | 42.40M | 848.00K | -46.00K |
Net Income | -14.64M | -12.83M | -6.59M | -1.35M | -778.00K | 42.82M | -15.96M | 53.44M | 7.43M | -9.79M | -7.32M | -12.20M | -61.42M | -19.86M | -20.48M | 9.21M | -358.07K | -7.64M | -11.46M | -20.95M | -12.68M |
Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 10.72% | -5.56% | 25.65% | 4.16% | -5.88% | -5.65% | -10.94% | -51.61% | -16.56% | -14.56% | 7.64% | -0.49% | -22.54% | -37.05% | -94.22% | -160.04% |
EPS | -0.72 | -1.57 | -0.84 | -0.17 | -0.10 | 1.20 | -0.53 | 1.91 | 0.27 | -0.37 | -0.29 | -0.49 | -2.51 | -0.82 | -0.86 | 0.50 | -0.12 | -2.63 | -4.04 | -7.33 | -5.23 |
EPS Diluted | -0.72 | -1.57 | -0.84 | -0.17 | -0.10 | 1.20 | -0.53 | 1.75 | 0.26 | -0.37 | -0.29 | -0.49 | -2.51 | -0.82 | -0.86 | 0.41 | -0.12 | -2.63 | -4.04 | -7.33 | -5.23 |
Weighted Avg Shares Out | 20.33M | 8.17M | 7.81M | 8.17M | 8.17M | 35.78M | 30.39M | 27.92M | 27.12M | 26.45M | 25.54M | 24.93M | 24.43M | 24.11M | 23.77M | 18.35M | 2.91M | 2.91M | 2.84M | 2.86M | 2.42M |
Weighted Avg Shares Out (Dil) | 20.33M | 8.17M | 7.81M | 8.17M | 8.17M | 35.78M | 30.39M | 30.49M | 29.09M | 26.45M | 25.54M | 24.93M | 24.43M | 24.11M | 23.77M | 22.66M | 2.91M | 2.91M | 2.84M | 2.86M | 2.42M |
HeartBeam AIMIGo™ Recognized for Digital Health Innovation in 8th Annual MedTech Breakthrough Awards Program
HeartBeam, Inc. (BEAT) Q1 2024 Earnings Call Transcript
HeartBeam Reports First Quarter 2024 Results
HeartBeam to Host First Quarter 2023 Results Conference Call on Thursday May 9, 2024 at 4:30 p.m. Eastern Time
HeartBeam Presents Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias
Gray Television's BEAT THE ODDS and SportsGrid Launch Partnership for National Syndication of Five Sports Betting Specials
BEAT Stock Earnings: HeartBeam Meets EPS for Q4 2023
HeartBeam, Inc. (BEAT) Q4 2023 Earnings Call Transcript
HeartBeam Reports Fourth Quarter and Full Year 2023 Financial Results
First Patients Enrolled in Pivotal Study Evaluating HeartBeam's AIMIGo™ System for Synthesizing a 12-Lead ECG
Source: https://incomestatements.info
Category: Stock Reports